Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
80 participants
OBSERVATIONAL
2014-06-30
2016-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Abdominal and Lower Extremity Compression During Tilt Table Testing in Adolescent POTS Patients
NCT01795469
Convulsions in Neonates With Congenital Heart Diseases
NCT06559410
Shunt Outcomes of Post-Hemorrhagic Hydrocephalus
NCT01480349
Paediatric Syncope in the Emergency Department
NCT05555771
The Ventricular Catheter Placement Study: Assessment of Efficacy and Safety of an Ultrasound Guided Shunt Insertion Technique
NCT01007786
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Prior to testing all medicines that can affect orthostatic tolerance will be held a minimum of 5 half-lives. Caffeine will be held for a minimum of 24 hours. Urinalysis (for urine specific gravity) and pregnancy testing (for female patients of child-bearing age) will be done the day of HUT testing. A recumbent EEG sample of no less than 10 minutes will be obtained. EKG leads, Holter leads, blood pressure monitors (beat-to-beat and conventional arm cuff), intravenous (IV) line, and sweat monitors will be placed. Sweat rate, EEG, and blood pressure monitoring will be synchronized by event trigger, allowing co-registration of all timed studies during data post-processing. Serum norepinephrine levels will be obtained at the time of IV placement and at 10 minutes of tilt or during/immediately after the syncope prodrome if syncope occurs prior to 10 minutes.
Once all monitors are placed, 10 minutes of EEG have been collected, and the patient has been recumbent for a minimum of 30 minutes, the table is tilted up-right to 70 degrees. A video camera will be on during the test. Patients are encouraged to report all symptoms and they are frequently examined for signs of pallor, acrocyanosis and sweating. Tilt testing is continued until syncope occurs, up to 10 minutes if the patient meets POTS criteria, or up to 45 minutes if neither syncope or POTS is not present.
Those who do meet age-appropriate POTS criteria (symptomatic heart-rate increment \>40 bpm or symptomatic total HR of \>130 bpm, all within 10 minutes of tilt for those \<20 years of age) will be lowered at 10 minutes (or sooner with syncope) and asked to repeat testing with abdominal and lower extremity compression. The compression suit has been used by Dr. Heyer in other NCH studies. It is composed of a Neoprene-like material with 5 Velcro straps that fit snugly around the legs, thighs and abdomen. The abdominal strap contains an air-filled bladder that potentiates abdominal compression. We have used the suit in over 30 consenting patients from prior study. None of the study participants complained of discomfort. The suit successfully reduced both heart rate and orthostatic symptoms in youth with POTS; 55% of studied patients no longer met POTS diagnostic criteria while the suit was on (see PMID: 24840763 for manuscript). We will use the compression suit as our method of attenuating POTS symptoms during HUT testing. EEG will be compared without and with compression.
The time frame for this study is on average 90 minutes. It will not exceed 3 hours. After lowering the tilt table, all monitor leads and the IV will be removed. Once leads are removed there are no further study obligations.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Syncope without POTS
Patients meeting syncope criteria without POTS. There will be no intervention for this study arm.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Referred to the neurology POTS and Syncope clinic at Nationwide Children's Hospital for clinical tilt table testing
* Has prior diagnosis or signs/symptoms of POTS (with or without syncope) or syncope (without POTS)
Exclusion Criteria
* Known seizure disorder
* Scalp or skull defect that could affect EEG amplitudes
* Pregnancy
* Non-English speaking
9 Years
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nationwide Children's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Geoffrey Heyer
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Geoffrey L Heyer, MD
Role: PRINCIPAL_INVESTIGATOR
Nationwide Children's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nationwide Children's Hopsital
Columbus, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Nationwide Children's Hospital POTS and Syncope clinic
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB14-00252
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.